<DOC>
	<DOC>NCT02264639</DOC>
	<brief_summary>This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.</brief_summary>
	<brief_title>A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>1. Male or Female 2. At least 18 years of age 3. Weigh &gt;55 kg 4. Diagnosed with PNH 5. On treatment with eculizumab (SolirisÂ®) for at least 3 months 6. Hb &lt; 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screening 7. Platelet count of &gt;30,000/mm3 8. Absolute neutrophil count &gt; 500/mm3 9. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study (see below) 10. Males with female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from donating sperm for the duration of the study 11. Willing and able to give informed consent 1. Active bacterial infection 2. Known infection with hepatitis B, C or HIV 3. Hereditary complement deficiency 4. History of bone marrow transplantation 5. Participation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 days 6. Evidence of QTcF prolongation defined as &gt; 450 ms for males and &gt; 470 ms for females at screening 7. Creatinine clearance (CrCl) &lt; 50 mL/min (CockcroftGault formula) at screening 8. Breastfeeding women 9. History of meningococcal disease 10. No vaccination against N. meningitidis types A, C, W, Y and B (administered as two separate vaccinations), Pneumococcal conjugate vaccine or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus influenzae Type B (Hib) vaccination within 2 years prior to Day 1 (Visit 2) dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>